Bio-Rad Appoints New CFO, Sarah E. Young

TL;DR

Bio-Rad just hired Sarah E. Young as CFO, starting Aug 19th. Big salary + stock options.

AI Summary

Bio-Rad Laboratories, Inc. announced on August 15, 2024, the appointment of Sarah E. Young as its new Chief Financial Officer, effective August 19, 2024. Young will receive an annual base salary of $450,000 and will be eligible for a discretionary annual bonus. She will also receive a stock option grant of 30,000 shares of Bio-Rad common stock.

Why It Matters

The appointment of a new CFO is a significant leadership change that can impact financial strategy and investor confidence.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and performance.

Key Numbers

• $450,000 — CFO Annual Base Salary (Represents the guaranteed compensation for the new Chief Financial Officer.)
• 30,000 — CFO Stock Options (Indicates the equity incentive granted to the new CFO as part of her compensation package.)

Key Players & Entities

• Bio-Rad Laboratories, Inc. (company) — Registrant
• Sarah E. Young (person) — Appointed Chief Financial Officer
• $450,000 (dollar_amount) — Annual base salary for new CFO
• 30,000 (dollar_amount) — Stock option grant for new CFO
• August 15, 2024 (date) — Date of report
• August 19, 2024 (date) — Effective date of CFO appointment

FAQ

Key Financial Figures

• $0.0001 — stered Class A Common Stock, Par Value $0.0001 per share BIO New York Stock Exchange
• $665,000 — other things, an annual base salary of $665,000 and a 2024 target cash bonus under the
• $2,500,000 — ncenzo restricted stock units valued at $2,500,000, and he also is eligible to participate
• $1.3 million — 2025. The offer letter also includes a $1.3 million sign-on bonus (minus applicable taxes)
• $150,000 — sehold goods relocation credit of up to $150,000, to be reimbursed based on submitted ex

Filing Documents

• bio-20240815.htm (8-K) — 42KB
• ex101-employmentofferlette.htm (EX-10.1) — 28KB
• bio-8k8202024xex991.htm (EX-99.1) — 7KB
• image_0a.jpg (GRAPHIC) — 3KB
• 0000012208-24-000054.txt ( ) — 253KB
• bio-20240815.xsd (EX-101.SCH) — 3KB
• bio-20240815_def.xml (EX-101.DEF) — 15KB
• bio-20240815_lab.xml (EX-101.LAB) — 27KB
• bio-20240815_pre.xml (EX-101.PRE) — 16KB
• bio-20240815_htm.xml (XML) — 4KB

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit Number Description 10.1 Employment Offer Let ter between the Company a nd Mr . DiVincenzo dated August 2, 2024 99.1 Press Release dated August 2 0 , 2024 104.1 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-RAD LABORATORIES, INC. Date: August 20, 2024 By: /s/ Courtney C. Enloe Courtney C. Enloe Executive Vice President, General Counsel & Secretary

View Full Filing

View this 8-K filing on SEC EDGAR